Here's Why Celanese (CE) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain Celanese (CE) in Your Portfolio
While Celanese (CE) faces challenges from demand softness and pricing pressures, it benefits from strategic acquisitions, expansion moves and productivity measures.
Why Celanese (CE) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Celanese's (CE) Q1 Earnings Surpass Estimates, Sales Lag
Net sales of Engineered Materials unit of Celanese (CE) decrease sequentially on lower volumes and prices in Q1.
Celanese (CE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare...
Countdown to Celanese (CE) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Celanese (CE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...
Celanese (CE) Achieves Milestones in the Acetyl Chain Business
Celanese (CE) achieves milestones in cost-effective, sustainable growth, including new facilities and supply contracts, positioning for earnings increase and global expansion.
Celanese (CE) Up 39% in 6 Months: What's Driving the Rally?
Celanese (CE) benefits from its productivity measures, investments in organic projects and strategic acquisitions.
Celanese (CE) Gets ISCC-Certified for Low Carbon CCU Methanol
Celanese (CE) now offers low-carbon choices to customers across its Acetyl Chain and Engineered Materials products under the ECO-CC name.
Celanese (CE) and Secarna Partner for Antisense Therapies
Celanese's (CE) collaboration with Secarna enables the development of a novel implant with the potential to significantly alter how disease-modifying ASO treatments are given.
Why Is Celanese (CE) Up 10% Since Last Earnings Report?
Celanese (CE) reported earnings 30 days ago. What's next for the stock?
Celanese: Appetite For Acquisitions Remains
Celanese's acquisition of DuPont's Mobility and Materials division did not bring the expected returns due to a challenging market environment. The company is currently saddled with a large debt and...
Celanese (CE) Announces Commercial Launch of Glaukos' iDose TR
iDose TR uses Celanese's (CE) VitalDose EVA. It is approved following the completion of two pivotal trials which demonstrates safety and efficacy.
7 Earnings Losers With a Shot at a Strong Comeback
While companies who rank among the earnings losers category don't obviously generate confidence, it's also important to keep in mind the big picture. Technology juggernaut Nvidia (NASDAQ: NVDA ) pr...
Celanese Corporation (CE) Q4 2023 Earnings Call Transcript
Celanese Corporation (CE) Q4 2023 Earnings Call Transcript
Related Companies